Chemometrics-Assisted Spectrophotometric Method Development and Validation for Simultaneous Estimation of Emtricitabine, Tenofovir Alafenamide Fumarate, and Dolutegravir Sodium in Dosage Form

Abstract

Aim: This study aims on the development of a chemometric-assisted spectroscopic method for the analysis of combined dosage form of emtricitabine (EMT), tenofovir alafenamide fumarate (TEN), and dolutegravir sodium (DOL). The use of a multivariate algorithm to analyse spectrophotometric data is a novel approach to estimating drug concentrations in formulations. Materials and Methods: The quantitative estimation of EMT, TEN, and DOL in tablets was carried out using four chemometric approaches: Classical least square (CLS), inverse least square, partial least square, and principal component regression. Thirty-two ternary mixtures of calibration sets and 16 mixtures of validation sets were prepared. The absorbance data matrix was attained by calculating absorbance at 25 different wavelengths in a range of 240-336 nm $(\Delta \lambda = 4 \text{ nm})$. The chemometric calculations were performed using Matlab2018a and Minitab software. The developed methods were validated. Results: The great accuracy of the current study was justified by the near-perfect recovery values (100%) and low standard deviation. For chemometrics approaches, the root mean square error of calibration (RMSEC), root mean square error of prediction (RMSEP), and root mean square error of cross-validation (RMSECV) outcomes display decent accuracy and precision. Conclusion: The CLS approach yielded the lowest predicted residual error sum of squares, RMSEC, RMSEP, and RMSECV scores. As a result, CLS might be regarded as the best chemometric approach among all techniques utilized. The label claim determined is in excellent accordance with the mean recoveries for EMT, TEN, and DOL. So, it can be used in quality control laboratories.

Keywords: Chemometrics, emtricitabine, spectrophotometric, tenofovir alafenamide fumarate and dolutegravir sodium

List of Abbreviations

Emtricitabine; EMT, Tenofovir Alafenamide Fumarate; TEN, Dolutegravir Sodium; DOL, Classical Least Square; CLS, Inverse Least Square; ILS, Partial Least Square; PLS, and Principal Component Regression; PCR, Standard deviation; SD, Root mean square error of Calibration; RMSEC, Root mean square error of Prediction; RMSEP, Root mean square error of Cross Validation; RMSECV, Predicted residual error sum of squares; PRESS, Analytical Reagent; A.R., Leave one out; LOO, correlation coefficient; R2, Figure of merits; FOM, Sensitivity; SEN, Limit of Detection; LOD, limit of quantitation; LOQ.

Introduction

In chemometrics, there are two types of data set namely, calibration and validation data set. The findings of calibration data set were utilized to determine the component concentrations in unknown sample.^[1] For both classical statistics and chemometric approaches, there is currently a considerable amount of computer software readily available.^[2] Chemometrics methods are particularly useful approaches for analyzing many compounds at the same time, in which the overlap of the active compounds' spectra generates an interference that makes determining the amounts of each component impossible.[3] In addition, chemometric calibration methods are simple since they can evaluate a large number of samples in a short amount of time more accurately and precisely compared with other methods. It can be described as the use of mathematical and statistical approaches to create and/or optimize measurement procedures, as well as the analysis of pertinent data to offer chemical information.[4] Multivariate calibrations such as classical least square (CLS), inverse least square (ILS), principle component regression (PCR), and partial least

How to cite this article: Rathod SM, Patel PU. Chemometrics-assisted spectrophotometric method development and validation for simultaneous estimation of emtricitabine, tenofovir alafenamide fumarate, and dolutegravir sodium in dosage form. J Rep Pharma Sci 2022;11:41-50.

Sapna M. Rathod, Paresh U. Patel¹

Research Scholar, Ganpat University, Kherva, Gujarat, India, ¹Department of Pharmaceutical Chemistry and Quality Assurance, S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, Gujarat, India

Received: 23 Jul 2021 **Accepted:** 01 Jan 2022 **Published:** 29 Jun 2022

Address for correspondence: Ms. Sapna M. Rathod, Research Scholar, Ganpat University, Kherva 384001, Gujarat, India. E-mail: srathod456@gmail.com



This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

square (PLS) have been widely used in quantitative spectrum analysis in recent years to extract selective information from unselective data.^[5,6] These approaches are commonly used since they produce the greatest outcomes when it comes to resolving complex mixtures.^[7] These approaches can be used to estimate medications in pharmaceutical formulations containing two or more drug components using simultaneous spectrophotometric methods.^[8] CLS and ILS are two of the most basic approaches, both based on Beer's principle and using a multivariate least square procedure. Factor analysis methods such as PCR and PLS are used to establish a link between chemical data matrices.^[9,10]

Emtricitabine (EMT), also known as 2',3'-dideoxy-5-fluoro-3'thiacytidine (FTC), is a synthetic nucleoside reverse transcriptase inhibitor (NRTI) that is taken once a day orally.^[11] Emtricitabine 5' triphosphate, an active metabolite formed by intracellular kinases phosphorylating emtricitabine, inhibits HIV reverse transcriptase by competing for entrance into the HIV DNA chain with the endogenous substrate 2'-deoxycitidine 5'-triphosphate.^[12] Because emtricitabine 5'-triphosphate lacks a hydroxyl group in the 3' position of the sugar moiety, it causes chain termination when it is incorporated into the HIV DNA chain.^[13,14]

Tenofovir alafenamide fumarate (TEN), chemically propan-2-yl(2S)-2-{[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl]amino}propanoate.^[15] TEN has a molecular weight of 476.47 g/mol and a chemical formula of $C_{21}H_{29}N_6O_5P$. TEN is a NRTI and tenofovir prodrug is used to treat HIV-1 infection. The drug has a solubility in water, methanol, and dimethyl sulfoxide.^[16,17]

Dolutegravir sodium (DOL) is integrase strand transfer inhibitor. The drug prevents the viral genome from being integrated into the host cell by blocking the strand transfer stage. It is chemically sodium; (3S,7R)-13-[(2,4-difluorophenyl) methylcarbamoyl] -7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8] tetradeca-10,13-dien-11-olate.^[18,19]

No reported analytical methods were found for estimating EMT, TEN, and DOL in bulk and in their combination dosage form. As a result, the current study was attempted to design and validate multivariate approaches for resolving complex drug spectra.

Instrumentation and Software

To test the absorbance of all the solutions, a shimadzu model 1700 (Japan) double beam UV/Visible spectrophotometer with a spectral width of 2 nm, wavelength accuracy of 0.5 nm, and a pair of 10 mm matched quartz cells was employed. The spectra of various calibration and validation sets were recorded using UV probe software. Chemometric calculations were performed using MATLAB-R2018a Software, Minitab 16.1.1, and Microsoft Excel 2010. MVC1toolbox (with MATLAB) was used to estimate figures of merit for multivariate calibration models.

Materials and Methods

TEN was kindly gifted by Bulat Pharmaceuticals, Hyderabad, Andhra Pradesh. EMT was provided as gift samples from Amneal Pharmaceuticals, Ahmedabad, Gujarat, and DOL were provided as gift samples from Cipla Pharmaceuticals, Mumbai, Maharashtra. The local market provided the commercial combination tablet (SPEGRA). Methanol (A.R.) grade (SD fine grade chemicals Ltd.), distilled water, and other chemicals used were of analytical grade. No. 41 Whatman filter paper was utilized in the study.

Preparation of solutions

Each drug was accurately weighed and transported to a separate volumetric flask and dissolved using methanol, and the volume was brought up to the mark using methanol (1000 μ g/mL). Aliquot each drug's standard stock solution to a separate volumetric flask to produce a working standard solution of 100 μ g/mL, using distilled water as diluent.

Preparation of calibration set and validation set

A data set of calibration samples was created using fractional factorial design. A total 32 ternary mixture solutions were prepared by mixing known amount of drugs under study in varied proportions. Validation set consisting of 16 samples was prepared from the working solutions in the same manner as that of calibration set. The composition of calibration as well as validation set were represented in Table 1.

Optimization and selection of method parameters

Sample solutions were analyzed across 200–400 nm for calibration and validation datasets, and zero-order spectra were obtained [Figure 1]. The absorbance data from the spectrum regions of 200–220 nm with noise and 350–400 nm with zero reading were excluded because they were not essential for the chemometric approach. Wavelength in the range of 240–336 nm was chosen to produce minimal root mean square error of calibration (RMSEC) and root mean square error of cross-validation (RMSECV) values.

Classical least square

CLS is also known as K matrix. Basically, it involves the usage of multiple linear regression to represent the Beer–Lambert law of spectroscopy in a classical way.

A = KC

Calibration set comprised of concentration matrix, C, and an absorbance matrix, A for known sets of samples is constructed to generate calibration using CLS. In MATLAB2018a software, the CLS model was developed by adding absorbance (A) and concentration matrix (C) data.

The calculated K can be used to forecast the concentration of an unknown sample, C_{unk} , based on its measured spectrum, and it can be stored as an absorbance matrix, A_{unk} .

There are mainly two subclasses of CLS namely, direct CLS and indirect CLS. The *K* matrix is calculated in direct CLS by measuring the spectra of the pure component, either neat or in a nonabsorbing solvent. In the indirect CLS technique, pure spectra are calculated from mixture spectra rather than being measured directly.

		*	Cali	bration Set			
MIX		Concentrations (µg	/mL)	MIX	Cone	centrations (µg/mL)	
	ЕМТ	TEN	DOL		ЕМТ	TEN	DOL
1	30	5	10	17	10	5	30
2	5	30	5	18	30	30	20
3	5	30	10	19	5	2	30
4	30	2	5	20	40	5	5
5	5	5	10	21	40	2	5
6	40	2	5	22	10	2	20
7	10	2	30	23	30	20	30
8	30	5	5	24	40	30	30
9	30	2	10	25	10	20	5
10	10	2	10	26	5	20	5
11	10	30	5	27	40	30	20
12	5	5	20	28	40	20	30
13	10	20	10	29	30	30	30
14	10	5	20	30	5	20	5
15	5	2	20	31	40	20	20
16	40	5	10	32	30	20	20
			Val	idation Set			
MIX		Concentrations (µg	/mL)	MIX	Cone	centrations (µg/mL)	÷
	EMT	TEN	DOL		ЕМТ	TEN	DOL
1	20	2	30	9	10	20	30
2	5	30	30	10	20	30	5
3	40	10	5	11	30	10	5
4	30	20	10	12	5	2	10
5	10	5	10	13	30	5	20
6	40	2	15	14	10	20	20
7	20	10	15	15	30	30	10
8	5	5	5	16	10	10	15

Table 1: Composition of calibration set and validation set for mixtures

EMT = emtricitabine, TEN = tenofovir alafenamide fumarate, DOL = dolutegravir sodium

Absorbance matrix A is comprised of zero-order spectra at 4 nm intervals between 240 and 336 nm, that is, absorbances at 25 wavelength points. The developed model comprised absorbance values of samples at 25 various wavelength points, and quantities of EMT, TEN, and DOL in the validation data set as well in tablet formulations were predicted.

Inverse least square

It is also called as P – matrix calibration as it originally requires the use of multiple linear regression to calculate the inverse expression of the Beer–Lambert equation of spectroscopy.

C = PA

where, C = concentration matrix,

P = calibration coefficient, and

```
A = absorbance matrix.
```

To determine P, a training set containing a concentration matrix, C, and an absorbance matrix, A, is used to create a calibration using ILS. ILS differs from the classical technique, which involves fitting a linear mixture of pure spectra to an unknown spectrum. This distinction provides ILS with several

advantages. When all of the system's components aren't explicitly evaluated, CLS fails to provide accurate predictions.

The software MATLAB2018a was used to construct the approach. The samples' absorbance values were inputted into the calibrations at 25 various wavelength points in the spectral area in a range of 240–336 nm. The concentrations of EMT, TEN, and DOL in validation set as well in tablets were predicted.

Partial least square and principal component regression

These are the most widely used methods in the multivariate calibration approach. The inverse calibration methodology is used in both procedures. The PCR is a method that operates on the principle of lowering the original data's dimensionality. The original variables are replaced with linear combinations of the variables in both PLS and PCR to solve the inversion problem (factors). The PCR employs the well-known singular value decomposition method. Using the converted data as input, this function was used to fit a PCR model. When fitting the PCR model, the leave-one-out (LOO) cross-validation approach was utilized. The optimal principal components (or eigenvectors) corresponding to the large eigenvalues are identified using cross-validation in the calibration step. The PLS employs a nonlinear



Figure 1: Overlay Spectra of 20.0 µg/mL solution of drugs; (a) tenofovir alafenamide fumarate, (b) emtricitabine, (c) dolutegravir sodium

iterative partial least square algorithm to generate the model. The independent and dependent variables are simultaneously compressed and decomposed, resulting in latent variables, in the PLS calibration using the orthogonalized PLS technique.

In Minitab 16.1.1, the A and C data matrix were incorporated in PCR and PLS models. The concentration of EMT, TEN, and DOL in the validation set and formulation were predicted. PLS and PCR calibrations were constructed by using the nonlinear iterative partial least squares (NIPALS) algorithm and standard singular value decomposition (SVD) algorithm, respectively. For PCR and PLS calibrations, an adequate number of principal components or factors must be chosen.

Validation of developed methods

Precision

Intraday and interday precision study was established by triplicate analysis of ternary mixture containing different proportions of EMT, TEN, and DOL (5/5/10 μ g/mL, 10/20/5 μ g/mL, and 10/20/10 μ g/mL) on one day and on three successive days, respectively. The absorbance data of the ternary mixture obtained after scanning in UV spectrophotometer were incorporated in respective equations and concentrations were calculated. The results were expressed as a percent recovery \pm standard deviation (SD).

Accuracy

The method's accuracy was determined by applying the analytical approach to fabricated blends of drug product components (placebo) to which known proportions of the drug ingredient to be analyzed were incorporated. Accuracy of the method was studied in triplicate at three various levels (80%, 100%, and 120%). The known amounts of standard solutions containing EMT (25.6, 32.0, and 38.4 µg/mL), TEN (3.2, 4.0, and 4.8 µg/mL), and DOL (6.4, 8.0, and 9.6 µg/mL), to achieve the various levels, were added to placebo sample solutions. The absorbance data of the ternary mixture obtained after scanning in UV spectrophotometer were incorporated in respective equations and concentrations were calculated. The results were expressed as a percent recovery \pm SD.

Assay of formulation

Weigh 10 spegra tablets and determine the average content of blend. The tablet powder equivalent to 100 mg EMT, 26.3 mg DOL (≈ 25 mg dolutegravir), and 15.6 mg TEN (≈ 12.5 mg tenofovir alafenamide) was transferred to volumetric flask and dissolved in methanol by sonication for 20 min and the volume was made up to the mark with methanol. Filter paper No. 41 (Whatman) was used to filter the solution. Aliquot required amount from the above solution to achieve 32 µg/mL EMT,

 $8.4 \,\mu$ g/mL DOL, and $5 \,\mu$ g/mL TEN. At the specified wavelengths, the absorbance of the sample solutions was recorded, and the amount of individual component was measured.

Results and Discussion

Classical least square

The value of calibration coefficient can be calculated by using the equation:

$$K = pinv(c) \times A$$

where, pinv(c) is the pseudo inverse of concentration matrix and A is matrix of absorbance of mixture.

$$K_{cal} = pinv(K)$$

where, pinv(K) is pseudo inverse of K matrix concentration of unknown:

$$C = K_{cal} \times A$$

Spectra of solutions containing unknown concentrations of drugs were recorded in the optimized range of wavelength and absorbance matrix A were generated. Using the calibration coefficient matrix K, the concentration was computed.

	Kcal Matrix [#]				bs mat	rix
	EMT	TEN	DOL	(1	Aixture)
	2.5817	-3.0432	1.3716		A ₂₄₀	
	1.912	1.583	-0.7103		A ₂₄₄	
	0.2503	7.4894	-2.5124		A ₂₄₈	
	-1.7189	12.0367	-3.1954		A ₂₅₂	
	-3.4584	13.9309	-2.6006		A ₂₅₆	
	-4.065	13.5792	-1.8539		A ₂₆₀	
	-3.2107	11.2118	-1.4085		A ₂₆₄	
	-1.0937	6.2445	-0.7398		A ₂₆₈	
	1.8526	0.5876	-0.5498		A ₂₇₂	
Conc matrix	4.6662	-5.1288	-0.2128		A ₂₇₆	
	6.836	-9.6667	0.0777		A ₂₈₀	
$\begin{bmatrix} C_{EMT} \\ C \end{bmatrix} =$	7.7676	-11.5561	0.0938	×	A ₂₈₄	
C_{TEN}	7.4444	-11.235	0.1188		A ₂₈₈	
	6.323	-10.0885	0.4681		A ₂₉₂	
	4.6298	-8.8943	1.3534		A ₂₉₆	
	2.5101	-7.5833	2.5921		A ₃₀₀	
	0.2221	-6.6484	4.2212		A ₃₀₄	
	-1.4785	-6.4007	5.6972		A ₃₀₈	
	-2.4641	-6.5054	6.7231		A ₃₁₂	
	-3.0195	-7.1512	7.6593		A ₃₁₆	
	-3.3878	-8.1195	8.6026		A ₃₂₀	
	-3.669	-9.2132	9.5248		A ₃₂₄	
	-3.8339	-10.5526	10.4599		A ₃₂₈	
	-4.008	-12.2572	11.6066		A ₃₃₂	
	-4.2149	-13.9382	12.7694		A ₃₃₆	

[#]For representation of matrix conveniently, Kcal values are shown in transposed form.

Where A is the absorbance values at 25 points corresponding to the 240–336 nm spectral range at an interval of 4 nm. $C_{\rm EMT}$, $C_{\rm TEN}$, and $C_{\rm DOL}$ represent the concentrations of EMT, TEN, and DOL, respectively.

Inverse least square

The value of calibration coefficient can be calculated by using the following equation:

$$P = pinv(A) \times C$$

Where, P is the matrix of the unknown calibration coefficients relating the concentrations to the spectral intensities. Spectra of solutions containing unknown concentrations of drugs mixture were recorded in the optimized range of wavelength and absorbance matrix A was generated. Using the calibration coefficient matrix P, the concentration was computed using the equation:

$$C = P \times A$$

		P matrix		A	bs mat	rix
	EMT	TEN	DOL	(A	<i>lixture</i>)
	284.4683	40.2716	110.4284		A ₂₄₀	
	-244.7356	-150.4681	9 8.9464		A ₂₄₄	
	243.2853	-88.8418	-140.6718		A ₂₄₈	
	-39.4257	144.8259	72.1366		A ₂₅₂	
	-139.9503	66.0755	51.2964		A ₂₅₆	
	-505.1327	110.8386	112.3062		A ₂₆₀	
	322.7066	-39.7513	36.8206		A ₂₆₄	
	79.2171	-73.261	-180.7986		A ₂₆₈	
	198.853	-81.6778	-20.4717		A ₂₇₂	
Conc matrix	323.0868	40.1419	34.6374		A ₂₇₆	
	-771.0162	43.4324	-70.437		A ₂₈₀	
$\begin{vmatrix} C_{EMT} \\ C \end{vmatrix} =$	-42.2148	24.783	-29.6429	×	A_{284}	
C_{TEN}	433.2921	20.8334	80.0165		A ₂₈₈	
	-447.1916	13.222	108.1144		A ₂₉₂	
	247.1869	-93.1218	46.8237		A ₂₉₆	
	211.0631	3.6621	-106.2136		A ₃₀₀	
	-162.7434	81.8123	90.8483		A ₃₀₄	
	-128.5652	-21.5662	-212.2727		A ₃₀₈	
	359.2401	23.6529	21.4378		A ₃₁₂	
	-41.094	4.9311	74.593		A ₃₁₆	
	-327.1792	16.5191	-39.0939		A ₃₂₀	
	555.3401	2.1758	-25.5125		A ₃₂₄	
	-433.031	-25.9353	-36.763		A ₃₂₈	
	-138.3896	27.1467	126.4679		A ₃₃₂	
	109.6559	-90.0582	34.8071		A ₃₃₆	

Where, A is the absorbance values at 25 points corresponding to the 240–336 nm spectral range at interval of 4 nm. $C_{\rm EMT}$, $C_{\rm TEN}$, and $C_{\rm DOL}$ represent the concentrations of EMT, TEN, and DOL, respectively.

Partial least square and principle component regression

The component number for the experimental data should be chosen in such a way that overfitting is avoided. The number of principal components determined using the following approaches:

For PCR, two PCs were selected based on retaining components with eigenvalues greater than 1 (and retain components that cumulatively explain 90% of the variance.) and it was confirmed using scree plot [Figure 2]. Scree plot shows steep curve up to three PCs, followed by a bend and then a flat line. A number of PCs in PLS selected using a model selection plot; scatterplot of the cross-validated R^2 and fitted R^2 values as a function of the number of components [Figure 2]. Three numbers of components were selected based on retaining components with identical R^2 values of validated R^2 and fitted R^2 . The components selected are also assessed using score plot. Here, the first two components make up the majority of the variance in the data, and there are no outliers in this data set; the points are spread randomly around zero.

The equations for the PLS method were obtained as:

$$\begin{split} C_{\rm EMT} &= 0.107 + 9.485 \times {\bf A1} + 28.863 \times {\bf A2} + 18.46 \times {\bf A3} - \\ 11.686 \times {\bf A4} - 11.264 \times {\bf A5} - 18.456 \times {\bf A6} - 10.271 \times {\bf A7} \\ &+ 3.293 \times {\bf A8} - 11.557 \times {\bf A9} - 9.722 \times {\bf A10} - 3.309 \times {\bf A11} \end{split}$$

 $\begin{array}{l} -4.031\times \mathbf{A12}-8.275\times \mathbf{A13}-5.134\times \mathbf{A14}+52.76\times \mathbf{A15}\\ -6.275\times \mathbf{A16}-64.879\times \mathbf{A17}+126.418\times \mathbf{A18}-55.385\times \mathbf{A19}-26.903\times \mathbf{A20}+33.011\times \mathbf{A21}-33.954\times \mathbf{A22}-0.849\times \mathbf{A23}-109.399\times \mathbf{A24}+89.03\times \mathbf{A25}\end{array}$

$$\begin{split} C_{\text{TEN}} &= 0.035 - 36.553 \times \text{A1} - 47.925 \times \text{A2} - 10.068 \times \text{A3} + \\ 58.874 \times \text{A4} + 44.355 \times \text{A5} + 30.864 \times \text{A6} + 2.532 \times \text{A7} - \\ 29.872 \times \text{A8} - 32.414 \times \text{A9} + 11.905 \times \text{A10} + 9.001 \times \text{A11} + \\ 10.04 \times \text{A12} + 29.664 \times \text{A13} + 44.557 \times \text{A14} - 95.969 \times \text{A15} \\ - 15.952 \times \text{A16} + 102.497 \times \text{A17} - 211.513 \times \text{A18} + 80.741 \times \\ \text{A19} - 61.178 \times \text{A20} + 6.754 \times \text{A21} + 155.712 \times \text{A22} - 20.279 \times \\ \text{A23} - 111.113 \times \text{A24} - 260.844 \times \text{A25} \end{split}$$

$$\begin{split} C_{\text{DOL}} &= -\ 0.172 + 19.94 \times \mathbf{A1} - 10.77 \times \mathbf{A2} - 27.725 \times \mathbf{A3} - 9.676 \times \mathbf{A4} - 3.541 \times \mathbf{A5} + 24.839 \times \mathbf{A6} + 11.394 \times \mathbf{A7} - 9.1 \times \mathbf{A8} + 1.65 \times \mathbf{A9} + 7.97 \times \mathbf{A10} + 0.778 \times \mathbf{A11} - 4.315 \times \mathbf{A12} + 4.747 \times \mathbf{A13} + 24.486 \times \mathbf{A14} + 0.708 \times \mathbf{A15} - 71.69 \times \mathbf{A16} + 150.532 \times \mathbf{A17} - 267.055 \times \mathbf{A18} + 53.179 \times \mathbf{A19} + 155.129 \times \mathbf{A20} - 23.697 \times \mathbf{A21} - 168.71 \times \mathbf{A22} - 30.047 \times \mathbf{A23} + 201.696 \times \mathbf{A24} - 1.725 \times \mathbf{A25} \end{split}$$

The equations for the PCR method were obtained as:

$$\begin{split} C_{\rm EMT} &= -\ 1.128 + 1.519 \times {\bf A1} + 0.937 \times {\bf A2} - 0.215 \times {\bf A3} - 1.501 \times {\bf A4} - 2.545 \times {\bf A5} - 2.937 \times {\bf A6} - 2.406 \times {\bf A7} - 0.914 \times {\bf A8} + 1.271 \times {\bf A9} - + 3.656 \times {\bf A10} + 5.860 \times {\bf A11} + 7.234 \times {\bf A12} + 7.563 \times {\bf A13} + 7.241 \times {\bf A14} + 6.397 \times {\bf A15} + 4.780 \times {\bf A12} + 7.563 \times {\bf A13} + 7.241 \times {\bf A14} + 6.397 \times {\bf A15} + 4.780 \times {$$



Figure 2: Plots for selection of number of component in PLS method for ternary mixture tenofovir alafenamide fumarate (TEN) (a), emtricitabine (EMT) (b), dolutegravir sodium (DOL) (c) and scree plot; for selection of component in PCR (d)

 $\begin{array}{l} \textbf{A16} + 2.080 \times \textbf{A17} - 0.865 \times \textbf{A18} - 2.814 \times \textbf{A19} - 3.660 \times \\ \textbf{A20} \text{ - } 3.981 \times \textbf{A21} - 4.131 \times \textbf{A22} - 4.072 \times \textbf{A23} - 3.995 \times \\ \textbf{A24} - 3.966 \times \textbf{A25} \end{array}$

$$\begin{split} C_{\text{TEN}} &= -\ 0.021 + 0.660 \times \mathbf{A1} + 2.985 \times \mathbf{A2} + 6.505 \times \mathbf{A3} + \\ 9.676 \times \mathbf{A4} + 11.730 \times \mathbf{A5} + 12.157 \times \mathbf{A6} + 10.802 \times \mathbf{A7} + \\ 7.162 \times \mathbf{A8} + 2.310 \times \mathbf{A9} - 3.218 \times \mathbf{A10} - 8.297 \times \mathbf{A11} - \\ 11.407 \times \mathbf{A12} - 12.227 \times \mathbf{A13} - 11.941 \times \mathbf{A14} - 11.261 \times \\ \mathbf{A15} - 9.945 \times \mathbf{A16} - 8.157 \times \mathbf{A17} - 6.689 \times \mathbf{A18} - 5.560 \times \\ \mathbf{A19} - 5.667 \times \mathbf{A20} - 6.437 \times \mathbf{A21} - 7.693 \times \mathbf{A22} - 9.922 \times \\ \mathbf{A23} - 12.885 \times \mathbf{A24} - 15.807 \times \mathbf{A25} \end{split}$$

$$\begin{split} C_{\text{DOL}} = 2.687 - 0.298 \times \mathbf{A1} - 0.962 \times \mathbf{A2} - 1.717 \times \mathbf{A3} - 2.172 \times \\ \mathbf{A4} - 2.274 \times \mathbf{A5} - 2.136 \times \mathbf{A6} - 1.924 \times \mathbf{A7} - 1.417 \times \mathbf{A8} - \\ 0.927 \times \mathbf{A9} - 0.285 \times \mathbf{A10} + 0.283 \times \mathbf{A11} + 0.599 \times \mathbf{A12} + \\ 0.713 \times \mathbf{A13} + 0.874 \times \mathbf{A14} + 1.317 \times \mathbf{A15} - 2.154 \times \mathbf{A16} + \\ 3.740 \times \mathbf{A17} + 5.659 \times \mathbf{A18} + 6.827 \times \mathbf{A19} + 7.627 \times \mathbf{A20} + \\ 8.297 \times \mathbf{A21} + 9.060 \times \mathbf{A22} + 10.125 \times \mathbf{A23} + 11.545 \times \mathbf{A24} + \\ 12.980 \times \mathbf{A25} \end{split}$$

Where, A is the absorbance values at 25 points corresponding to the 240–336 nm spectral range at intervals of 4 nm and C_{EMT} , C_{TEN} , and C_{DOL} are the concentrations of EMT, TEN, and DOL, respectively.

Method validation

Precision

Method reproducibility for each title ingredient was demonstrated by repeatability and intermediate precision measurements. The obtained results within and between days trials are represented in Tables 2 and 3. The recovery values were close to 100% with low SD justified the good precision of the proposed methods.

Accuracy

The mean percent recoveries for EMT, TEN, and DOL are reported in Table 4. The remarkable accuracy of the

Table 2: Precision data (intraday) by chemometric methods					
Chemometric model	Ternary mixture (µg/mL) (EMT/TEN/DOL)	% Re	% Recovery, mean \pm SD ($n = 3$),		
		EMT	TEN	DOL	
CLS	1 (5/5/10)	99.6 ± 0.801	100.2 ± 1.709	99.74 ± 0.709	
	2 (10/20/5)	$99.87 \!\pm\! 0.803$	99.92 ± 0.326	99.47 ± 1.223	
	3 (10/20/10)	99.94 ± 0.809	$100.07 \!\pm\! 0.417$	$100.27 \!\pm\! 0.851$	
ILS	1 (5/5/10)	99.87 ± 1.617	99.4 ± 1.201	99.84 ± 0.751	
	2 (10/20/5)	100.3 ± 0.755	99.69 ± 0.576	99.74 ± 1.528	
	3 (10/20/10)	99.84 ± 0.612	$100.09 \!\pm\! 0.476$	99.5 ± 0.755	
PLS	1 (5/5/10)	100.54 ± 1.007	99.94 ± 1.528	99.8 ± 0.529	
	2 (10/20/5)	99.6 ± 0.954	99.8 ± 0.399	100.34 ± 1.748	
	3 (10/20/10)	100.37 ± 1.041	100.12 ± 0.276	100.67 ± 0.908	
PCR	1 (5/5/10)	99.54 ± 1.102	99.6 ± 1.778	100.14 ± 1.202	
	2 (10/20/5)	99.57 ± 1.107	100.22 ± 0.653	100.27 ± 1.102	
	3 (10/20/10)	$100.24 \!\pm\! 0.951$	$100.09 \!\pm\! 0.389$	100.57 ± 1.151	

EMT = emtricitabine, TEN = tenofovir alafenamide fumarate, DOL = dolutegravir sodium, CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, SD = standard deviation

	Table 3: Precision data (interday) by chemometric methods						
Chemometric model	Ternary mixture (µg/mL)	% Recov	% Recovery, mean \pm SD ($n = 3$),				
	(EMT/TEN/DOL)	ЕТ	TEN	DOL			
CLS	1 (5/5/10)	100.32 ± 1.659	100.34 ± 1.446	99.69±1.069			
	2 (10/20/5)	99.94 ± 0.809	99.91 ± 0.563	100.38 ± 1.509			
	3 (10/20/10)	100.05 ± 0.775	99.89 ± 0.615	99.81 ± 1.089			
ILS	1 (5/5/10)	99.98 ± 1.069	100.19 ± 1.327	99.73 ± 0.954			
	2 (10/20/5)	99.62 ± 0.968	99.66 ± 0.412	$99.89 \!\pm\! 1.201$			
	3 (10/20/10)	$99.39 \!\pm\! 1.059$	99.82 ± 0.476	$99.53 \!\pm\! 0.759$			
PLS	1 (5/5/10)	100.03 ± 1.348	99.96 ± 1.208	99.85 ± 1.004			
	2 (10/20/5)	99.77 ± 1.036	100.04 ± 0.539	100.14 ± 1.229			
	3 (10/20/10)	100.17 ± 1.012	99.88 ± 0.645	99.91 ± 1.245			
PCR	1 (5/5/10)	99.96 ± 1.253	100.05 ± 1.334	99.66 ± 0.987			
	2 (10/20/5)	100.14 ± 0.945	99.91 ± 0.539	100.47 ± 1.158			
	3 (10/20/10)	100.04 ± 1.023	99.97 ± 0.409	99.58 ± 0.902			

EMT = emtricitabine, TEN = tenofovir alafenamide fumarate, DOL = dolutegravir sodium, CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, SD = standard deviation

recommended approaches was justified by the near-100% recovery values with low SD.

Chemometric methods

LOO approach was employed for cross validation technique using calibration set of 32 mixtures. Each calibration sample's predicted concentrations were tested to the known concentrations of compounds. RMSECV and RMSEP were calculated to validate the model. For a given model, these values must be as low as possible. For assessing the inaccuracies in the predicted concentrations, the RMSECV value was utilized as a screening test. It denotes the precision as well as the accuracy of predictions.

The prediction capabilities of developed methods (CLS, ILS, PCR, and PLS) are evaluated by using two different methods. Plotting the known concentration against the predicted concentration was the first approach used. The aforesaid

chemometric procedures [Tables 5-7] yielded a reasonable correlation coefficient (R^2) value for each drug, and the second way was the calculation of RMSECV and RMSEP.

The analytical figure of merits (FOM) is critical for quantifying the quality of an approach or comparing methods. Several FOM has been observed in multivariate calibration, including sensitivity (SEN), analytical sensitivity, the limit of detection (LOD), and limit of quantitation (LOQ) [Tables 5-7].

Assay of formulation

EMT, TEN, and DOL in tablet formulations were assessed using the proposed chemometric approach. The results were satisfactory and in line with the label claim. The assay results [Table 8] show that the approach is acceptable for simultaneous quantification of EMT, TEN, and DOL without intervention from common excipients.

	Table 4: Accuracy data of chemometric methods (CLS, ILS, PLS, and PCR)							
Drug	Level (%)	Std. spiked (µg/mL)		% Recovery mean ±	SD			
			(n=3)					
			CLS	ILS	PLS	PCR		
EMT	80	25.6	99.99 ± 0.314	99.99 ± 0.216	100.11 ± 0.239	100.07 ± 0.294		
	100	32	$100.12 \!\pm\! 0.408$	$99.97 \!\pm\! 0.355$	$100.05 \!\pm\! 0.338$	$100.11 \!\pm\! 0.144$		
	120	38.4	$100.14 \!\pm\! 0.209$	$100.09 \!\pm\! 0.289$	$100.19 \!\pm\! 0.291$	$100.08 \!\pm\! 0.105$		
TEN	80	3.2	$99.48 \!\pm\! 1.302$	$100.53 \!\pm\! 0.955$	99.48 ± 1.302	$99.48 \!\pm\! 0.955$		
	100	4	99.92 ± 1.259	$99.42 \!\pm\! 1.259$	$99.59 \!\pm\! 1.259$	$100.17 \!\pm\! 1.377$		
	120	4.8	100.56 ± 1.148	$99.94 \!\pm\! 1.273$	$100.56 \!\pm\! 1.148$	$99.94 \!\pm\! 1.273$		
DOL	80	6.4	100.21 ± 0.942	100.42 ± 0.651	99.64 ± 0.549	99.59 ± 0.861		
	100	8	100.29 ± 0.711	$100.17 \!\pm\! 0.878$	$100.38 \!\pm\! 0.573$	100.09 ± 0.764		
	120	9.6	$100.08 \!\pm\! 0.684$	100.18 ± 0.637	$100.39 \!\pm\! 0.47$	$99.69 \!\pm\! 0.478$		

EMT = emtricitabine, TEN = tenofovir alafenamide fumarate, DOL = dolutegravir sodium, CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, SD = standard deviation

Table 5: Statistical parameters and figure of merits for emtricitabine						
Component	Emtricitabine					
Parameters/model	CLS	ILS	PLS	PCR		
RMSEC	0.1928	0.8965	0.2348	0.2597		
RMSECV	0.1866	0.9965	0.1906	0.2235		
RMSEP	0.9797	1.02923	1.1929	1.3193		
R^2 Calibration	0.9998	0.9994	0.9998	0.9997		
R^2 Prediction	0.995	0.993	0.999	0.996		
Intercept	0.427	0.397	-0.019	0.225		
Slope	0.992	0.976	0.998	0.999		
PRESS	1.114	6.268	1.168	1.599		
Sensitivity (SEN)	0.00858	0.0108	0.01641	0.01969		
Selectivity (SEL)	0.0328	0.0418	0.0627	0.00752		
LOD, µg/mL	0.222	0.196	0.153	0.121		
LOQ, µg/mL	0.675	0.537	0.465	0.368		
Analytical sensitivity (γ), mL/μg	13.5	14.7	19.5	24.7		

CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, RMSEC = root mean square error of calibration, RMSECV = root mean square error of cross validation, RMSEP = root mean square error of prediction, PRESS = predicted residual error sum of squares, LOD = limit of detection, LOQ = limit of quantitation

Table 6: statistical parameters and figure of merits for tenofovir alafenamide fumarate							
Component	Tenofovir alafenamide fumarate						
Parameters/model	CLS	ILS	PLS	PCR			
RMSEC	0.368	0.9136	0.412	0.462			
RMSECV	0.433	1.13837	0.361	0.389			
RMSEP	2.7919	1.175703	3.1251	3.5054			
R^2 Calibration	0.9985	0.9982	0.9989	0.9987			
R^2 Prediction	0.992	0.991	0.999	0.991			
Intercept	0.657	-0.185	-0.025	0.597			
Slope	0.964	1.044	1.001	0.965			
PRESS	6.018	8.639	4.181	4.844			
Sensitivity (SEN)	0.00345	0.0053	0.0067	0.0071			
Selectivity (SEL)	0.0103	0.039	0.0203	0.0213			
LOD, µg/mL	0.616	0.569	0.3637	0.3369			
LOQ, µg/mL	1.87	1.29	1.1	1.02			
Analytical sensitivity (γ), mL/ μ g	4.87	5.38	8.25	8.91			

CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, RMSEC = root mean square error of calibration, RMSECV = root mean square error of cross validation, RMSEP = root mean square error of prediction, PRESS = predicted residual error sum of squares, LOD = limit of detection, LOQ = limit of quantitation

Table 7: Statis	Table 7: Statistical parameters and figure of merits for dolutegravir sodium					
Component	Dolutegravir sodium					
Parameters/model	CLS	ILS	PLS	PCR		
RMSEC	0.582	0.976	0.441	0.492		
RMSECV	0.452	1.284	0.581	0.644		
RMSEP	3.963	1.326	3.003	3.353		
R^2 Calibration	0.9997	0.9988	0.9983	0.9994		
R^2 Prediction	0.996	0.982	0.999	0.987		
Intercept	0.627	0.663	0.076	-0.186		
Slope	1.007	0.991	1.001	0.983		
PRESS	6.555	15.364	10.819	13.31		
Sensitivity (SEN)	0.00246	0.0068	0.00744	0.009179		
Selectivity (SEL)	0.00692	0.0156	0.02094	0.0258		
LOD, µg/mL	0.847	0.734	0.327	0.26		
LOQ, µg/mL	2.57	1.69	0.991	0.79		
Analytical sensitivity (γ), ml/μg	3.59	7.86	9.17	11.15		

CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, RMSEC = root mean square error of calibration, RMSECV = root mean square error of cross validation, RMSEP = root mean square error of prediction, PRESS = predicted residual error sum of squares, LOD = limit of detection, LOQ = limit of quantitation

Table 8: Content of emtricitabine, tenofovir alafenamide fumarate and dolutegravir sodium by chemometrics method					
Drug		EMT	TEN	DOL	
Label claim (mg in tablet)		200	25	50	
% Label claim, mean \pm SD, ($n = 3$)	CLS	100.09 ± 0.284	100.81 ± 0.835	$100.38 \!\pm\! 0.819$	
	ILS	100.02 ± 0.239	99.67 ± 1.011	99.71 ± 0.711	
	PLS	100.08 ± 0.141	100.42 ± 1.128	100.34 ± 0.506	
	PCR	99.94 ± 0.256	99.75 ± 1.392	99.84 ± 1.003	

EMT = emtricitabine, TEN = tenofovir alafenamide fumarate, DOL = dolutegravir sodium, CLS = classical least square, ILS = inverse least square, PLS = partial least square, PCR = principle component regression, SD = standard deviation

Conclusion

The chemometric method is more accurate and precise than conventional methods as the total absorbance of the ternary mixture was measured. The developed method holds an acceptable degree of precision and accuracy in accordance with international guidelines. With great recoveries and precision, the proposed approach was successfully used to the assay of formulation. As a result, the current method can be used to estimate EMT, TEN, and DOL in formulation simultaneously.

Acknowledgement

The authors express gratitude towards Bulat Pharmaceuticals, Amneal Pharmaceuticals, Cipla Pharmaceuticals for gifting drug samples. The authors also acknowledge APMC College of Pharmaceutical Education and Research, Himatnagar (Managed by Himatnagar Kelvani Mandal) for providing facilities to conduct this research.

Financial support and sponsorship

Nil.

Conflicts of interest

I/we certify that no actual or potential conflict of interest in relation to this article exists.

References

- 1. Kramer R. Chemometric Techniques for Quantitative Analysis. New York: Marcel Dekker Inc; 1998.
- Beebe KR, Pell RJ, Seasholtz MB, Chemometrics: A Practical Guide. 1st ed. New York: Wiley Interscience; 1998.
- 3. Miller JN, Miller JC. Statistics and Chemometrics for Analytical Chemistry. 6th ed. Harlow: Pearson Education Limited; 2005.
- Goicoechea HC, Olivieri AC. Simultaneous determination of rifampicin, isoniazid and pyrazinamide in tablet preparations by multivariate spectrophotometric calibration. J Pharm Biomed Anal 1999;20:681-6.
- Patel NS, Nandurbarkar VP, Patel AJ, Patel SG. Simultaneous spectrophotometric determination of celecoxib and diacerein in bulk and capsule by absorption correction method and chemometric methods. Spectrochim Acta A Mol Biomol Spectrosc 2014;125:46-52.
- Nejem RA, Issa MM, Shanab AA, Shat NA. Double divisor mean centering of ratio spectra as a developed spectrophotometric method for the analysis of five-component mixture in drug analysis. J Saudi Chem Soc 2017;21:S283-92.
- Rathod SM, Patel PU. Chemometrics assisted spectroscopic method development and validation for simultaneous determination of sofosbuvir and daclatasvir dihydrochloride in tablet formulation. Indian Drugs 2020;57:37-46.
- Patel NC, Patel AP, Patel JK. Development and validation of chemometrics assisted UV spectrophotometric method for epigallocatechin gallate and curcumin in tablet formulation. Indian Drugs 2020;57:45-54.

- Sankar ASK, Vetrichelvan T, Venkappaya D, Divya O. Simultaneous estimation of ramipril, aspirin and atorvastatin calcium by classical least squares regression in capsule dosage form. Res J Pharm Technol 2011;4:398-401.
- Patel A, Gohel M, Soni T. Partial least square analysis and mixture design for the study of the influence of composition variables on nanoemulsions as drug carriers. Res J Pharm Technol 2014;7:1446-55.
- 11. Pathi PJ, Reddy PR, Raju NA. Visible spectrophotometric estimation of emtricitabine in pharmaceutical formulations. Res J Pharm Technol 2011;4:437-40.
- Halde S, Mungantiwar A, Chintamaneni M. Determination of emtricitabine in human plasma by LC-MS/MS. Res J Pharm Technol 2012;5:133-7.
- Shah AU, Kotadiya VV, Ajmera AA. Analytical method development and validation for simultaneous estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form. Res J Pharm Technol 2016;9:463-8.
- Narendra A, Deepika D, Annapurna M. Determination of emtricitabine by derivative spectrophotometric method in pharmaceutical dosage forms. Chem Sci Trans 2013;2:978-82.
- Aggarwal NN, Bhat KI, Jacob JT. Stability indicating assay method development and validation for tenofovir alafenamide fumarate by RP-HPLC. Pharm Anal Acta 2018;9:1-6.
- Bhavyasri K, Manisha M. UV-spectrophotometric estimation and forced degradation studies of tenofovir alafenamide fumarate (TAF) in its bulk and tablet dosage form. Res J Pharm Technol 2020;13:1231-5.
- 17. Mastanamma SK, Saidulu P, Srilakshmi B, Ramadevi N, Prathyusha D, Vidya Rani M. Analytical quality by design approach for the development of UV-spectophotometric method in the estimation of tenofovir alafenamide in bulk and its laboratory synthetic mixture. Res J Pharm Technol 2018;11:499-503.
- Rathod SM, Patel PU. Development and validation of RP–HPLC method for estimation of lamivudine and dolutegravir sodium in synthetic mixture. Res J Pharm Technol 2020;3:2864-8.
- Devanna N, Dudekula B, Ramachandraiah C. Development and validation for the simultaneous estimation of dolutegravir and lamivudine in drug product by RP-HPLC. Int J Res Pharm Nano Sci 2017;6:173-80.